| ...
| Question Does adding ivermectin, an inexpensive and widely
| available antiparasitic drug, to the standard of care
| reduce the risk of severe disease in patients with COVID-19
| and comorbidities?
|
| Findings In this open-label randomized clinical trial of
| high-risk patients with COVID-19 in Malaysia, a 5-day
| course of oral ivermectin administered during the first
| week of illness did not reduce the risk of developing
| severe disease compared with standard of care alone.
|
| Meaning The study findings do not support the use of
| ivermectin for patients with COVID-19.
| ...
<https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362?guestAccessKey=58760460-df0f-4790-9257-8f3682dca39b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021822>

--bks